StockData
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. (MCRB) stock

MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.41+0.00 (0.00%)

Close on Nov 17, 2026Market cap $14.02MP/E –Yield –

Seres Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Seres Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -4462.8%. For fiscal 2025 it was -11910.1%, against -2524.0% the year before. The highest annual figure on record is -44.5% in fiscal 2021.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-11910.1%−9386.1
FY2022Dec 31, 2022-2524.0%−2479.5
FY2021Dec 31, 2021-44.5%+220.8
FY2020Dec 31, 2020-265.3%−57.0
FY2019Dec 31, 2019-208.3%+146.5
FY2018Dec 31, 2018-354.8%−70.1
FY2017Dec 31, 2017-284.7%+141.8
FY2016Dec 31, 2016-426.5%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-2890.4%+54959.6
Q1 FY2026Mar 31, 2026-5839.9%+8542.6
Q4 FY2025Dec 31, 2025-4424.0%−4463.1
Q3 FY2025Sep 30, 2025-6403.7%−6226.2
Q4 FY2023Dec 31, 2023-57850.0%−56133.8
Q3 FY2023Sep 30, 2023-14382.6%−9174.9
Q2 FY2023Jun 30, 202339.2%+3773.3
Q4 FY2022Dec 31, 2022-177.5%+507.0
Q3 FY2022Sep 30, 2022-1716.2%−1770.2
Q2 FY2022Jun 30, 2022-5207.6%−4292.9
Q1 FY2022Mar 31, 2022-3734.2%−3116.4
Q4 FY2021Dec 31, 2021-684.6%−582.7
Q3 FY2021Sep 30, 202154.0%+2170.8
Q2 FY2021Jun 30, 2021-914.7%−574.9
Q1 FY2021Mar 31, 2021-617.8%−377.3
Q4 FY2020Dec 31, 2020-101.9%+149.9
Q3 FY2020Sep 30, 2020-2116.8%−1872.4
Q2 FY2020Jun 30, 2020-339.9%−252.5
Q1 FY2020Mar 31, 2020-240.5%+94.9
Q4 FY2019Dec 31, 2019-251.8%−47.9
Q3 FY2019Sep 30, 2019-244.4%+0.9
Q2 FY2019Jun 30, 2019-87.4%+522.7
Q1 FY2019Mar 31, 2019-335.4%+376.4
Q4 FY2018Dec 31, 2018-203.9%+770.4
Q3 FY2018Sep 30, 2018-245.3%−213.5
Q2 FY2018Jun 30, 2018-610.1%+332.7
Q1 FY2018Mar 31, 2018-711.8%+146.9
Q4 FY2017Dec 31, 2017-974.3%−128.2
Q3 FY2017Sep 30, 2017-31.8%+114.9
Q2 FY2017Jun 30, 2017-942.8%–
Q1 FY2017Mar 31, 2017-858.7%–
Q4 FY2016Dec 31, 2016-846.1%–
Q3 FY2016Sep 30, 2016-146.7%–

More Seres Therapeutics figures

See a number that looks wrong?